Sleep Better Columbus is now offering FDA-cleared oral appliance therapy for patients diagnosed with mild to moderate ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

“REM sleep is when your brain does some of its most important cleanup and memory storage work,” said co-corresponding author ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

Obstructive Sleep Apnea (OSA) remains a widespread yet under-treated condition, affecting millions globally. Traditional treatments such as CPAP therapy, w | Drug Discovery And Development ...

Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and acros ...

Greater obstructive sleep apnea (OSA)-related hypoxemia is associated with frontoparietal cerebrovascular pathology, which is linked to reduced medial temporal lobe (MTL) integrity and impaired ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA.

The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving at least a 50% reduction in apnea-hypopnea index. Results from the pivotal ...